The New RSV Vaccines for Older Adults: What Adults Over 60 and their Care Providers Need to Know

Respiratory syncytial virus (RSV) is one of the main respiratory viruses that impacts the health and well-being of Canadians. Even though most children will have experienced their first RSV infection by the age of two, adults 65 years and older experience more complications, with this age group having the highest mortality rate attributable to RSV infections.

The first of a new series of RSV vaccines has recently been approved for the first time in Canada, however, a lot more work needs to be done to promote and support improved access to vaccines among older Canadians.

Join us for an expert discussion with Dr. Samir Sinha, Geriatrician and Professor of Medicine, University of Toronto and Director of Health Policy Research at the NIA, Dr. Marla Shapiro, Professor of Family Medicine, University of Toronto and Dr. Zain Chagla, Associate Professor of Medicine, McMaster University and Infectious Diseases Consultant that shares updated information on the significant impact RSV infections can have on the health and wellbeing of older adults and what you need to know about the new RSV vaccines that are now available for Canadians 60 years and older.

Accessibility Information

We strive to present accessible and inclusive events. If you have specific accommodation questions or needs, please contact alice.sk@torontomu.ca. Live captioning will be available for this event.

REGISTER HERE